STAT+: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” . That could curb
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
